Abstract:One of the most common causes of cancer mortality worldwide is hepatocellular carcinoma (HCC). Extracellular signal-regulated kinase (ERK1/2) pathway has been shown to play an important role in the development and progression of HCC. Here, we demonstrate that the immunosuppressive agent cyclosporin A (CsA) has the ability to increase the cellular growth in HCC (HepG2 cells) via activation of ERK1/2 signaling cascade. It was found that ERK1/2 phosphorylation induced by CsA was highly reduced in the presence of the reactive oxygen species (ROS) scavenger polyethylene glycol-superoxide dismutase (PEG-SOD). Furthermore, it was observed that inhibition of metalloproteinase activity using TAPI-2 prevents ERK1/2 activation by CsA. Moreover, a disintegrin and metalloproteinase domain 17 (ADAM-17) activity was found to be critical for ERK phosphorylation by CsA. In addition, CsA-induced ERK phosphorylation was highly reduced in the presence of either neutralizing anti-heparin-binding-epidermal growth factor (HB-EGF) antibody or UO126 (MEK inhibitor). By using the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor AG1478, it was found that EGFR is critical for ERK phosphorylation induced by CsA. Furthermore, CsA-induced cell proliferation was strongly reduced in the presence of either PEG-SOD or TAPI-2 or neutralizing anti-ADAM17 antibody or neutralizing anti-HB-EGF antibody or AG1478 or UO126. Collectively, these data demonstrate that CsA has the ability to activate ERK1/2 signaling cascade that could be translated into an increase in HepG2 cell proliferation. Furthermore, these data support the role of ROS, ADAM-17, and EGFR in ERK1/2 signaling activation and subsequent cell proliferation induced by CsA in HepG2 cells.

Cyclophilin A is upregulated in small cell lung cancer and activates ERK1/2 signal.

The Progress of Cyclophilin A in Cancer Research

Cyclophilin A Inhibits A549 Cell Oxidative Stress And Apoptosis By Modulating The Pi3k/Akt/Mtor Signaling Pathway

Cyclophilin A: promising target in cancer therapy

Cyclophilin A Promotes Human Hepatocellular Carcinoma Cell Metastasis Via Regulation of Mmp3 and Mmp9

Cyclophilin B promotes cell proliferation, migration, invasion and angiogenesis via regulating the STAT3 pathway in non-small cell lung cancer.

Epac1 is Involved in Cell Cycle Progression in Lung Cancer Through PKC and Cx43 Regulation

Cyclophilin J Is a Novel Peptidyl-Prolyl Isomerase and Target for Repressing the Growth of Hepatocellular Carcinoma

Cypa, A Gene Downstream Of Hif-1 Alpha, Promotes The Development Of Pdac

Clinical significance of cyclophilin a expression in esophageal squamous cell carcinoma.

Identification Of Cyclophilin A As A Potential Prognostic Factor For Clear-Cell Renal Cell Carcinoma By Comparative Proteomic Analysis

Upregulation of CPE promotes cell proliferation and tumorigenicity in colorectal cancer

Oligo-microarray analysis reveals the role of cyclophilin A in drug resistance

Cyclophilin A (cypa) Induces Chemotaxis Independent of Its Peptidylprolyl Cis-Trans Isomerase Activity

Cyclophilin A Regulates the Apoptosis of A549 Cells by Stabilizing Twist1 Protein.

Cyclophilin D: Guardian or Executioner for Tumor Cells?

Secreted cyclophilin A is non-genotoxic but acts as a tumor promoter

Potential Role of Cyclophilin A in Regulating Cytokine Secretion

CD147 stimulates hepatoma cells escaping from immune surveillance of T cells by interaction with Cyclophilin A.

Cyclophilin A associates with and regulates the activity of ZAP70 in TCR/CD3-stimulated T cells

Cyclosporin A activates human hepatocellular carcinoma (HepG2 cells) proliferation: implication of EGFR-mediated ERK1/2 signaling pathway